Results 221 to 230 of about 55,060 (310)
The application of DM-MSTP method on Tunisian financial market: 2024 case study. [PDF]
Dhouib S +4 more
europepmc +1 more source
Aims Hypertension is a leading modifiable risk factor for cardiovascular mortality worldwide. This study aimed to evaluate 25‐year trends in antihypertensive agent (AHA) utilization in Croatia between 2000 and 2024. Methods We conducted a national, population‐based analysis using IMS and IQVIA pharmaceutical databases.
Andrej Belančić +4 more
wiley +1 more source
Modeling Saudi stock index returns and volatility: a dual approach using GARCH and neural networks. [PDF]
Al-Besher S, Al-Najjar D.
europepmc +1 more source
Abstract Aim The aim of this study was to assess the general and product‐specific experiences of MAHs use of RWD/RWE in medicines development and in their regulatory submissions, and to explore organizational aspects of MAHs related to RWD/RWE. Methods An electronic survey was conducted, and information collected directly from MAHs.
Sini M. Eskola +5 more
wiley +1 more source
A 2000-2023 dataset for measuring China's biodiversity risk. [PDF]
Chen ZH, Gao X, Yang JR, Yarovaya L.
europepmc +1 more source
Zuranolone: A case study in (regulatory) rush to judgement?
Abstract Sage, in collaboration with Biogen, submitted a new drug approval for zuranolone for postpartum depression (PPD) and major depressive disorder (MDD) in December 2022. In August 2023, the US Food and Drug Administration granted approval for PPD but denied approval for MDD.
Lisa Cosgrove +4 more
wiley +1 more source
FusionLSTM-CNF: a confidence-calibrated multi-modal late fusion framework for robust stock movement prediction under uncertainty. [PDF]
Wang TW +4 more
europepmc +1 more source
Abstract Aims Risk minimization measures (RMMs) are key regulatory tools to ensure safe medicinal product use. Regulatory guidelines recommend pre‐specifying the targets, or ‘thresholds’, for assessing RMM effectiveness. We aimed to review recent industry‐sponsored post‐authorization safety studies (PASS) that evaluated the effectiveness of RMMs ...
Kexin Zhu +7 more
wiley +1 more source
Risk-taking responses to crash experience: Evidence from China. [PDF]
Fang Z, Xu H, Mu Y.
europepmc +1 more source
Pharmacokinetic interactions between Echinacea and two antiviral drugs, favipiravir and atazanavir, were assessed in rats. The findings suggest that Echinacea does not significantly affect the pharmacokinetics of favipiravir and atazanavir. These results provide preliminary evidence that concurrent use of Echinacea with these antiviral drugs may be ...
Siva Nageswara Rao Gajula +4 more
wiley +1 more source

